Biotech · Private company
PYC Therapeutics
Track this companyFree. Adds PYC Therapeutics to your Dealase workspace and tells you when its record changes.
Clinical trials52 recruiting or active
Pipeline programs2From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline2
- VP-001Phase 2 · Retinitis Pigmentosa 11ClinicalTrials.gov · fetched Nov 12, 2026
- VP-001Phase 1 · Retinal DystrophyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Jun 1, 2025ClinicalTrials.gov NCT06852963 · fetched Nov 12, 2026
- MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)PHASE1 · COMPLETED · started Jun 13, 2024ClinicalTrials.gov NCT06455826 · fetched Nov 12, 2026
- Natural History of Autosomal Dominant Optic Atrophy (ADOA), Caused by OPA1 MutationTERMINATED · started Feb 28, 2024ClinicalTrials.gov NCT06140329 · fetched Nov 12, 2026
- SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy SubjectsPHASE1 · COMPLETED · started Apr 20, 2023ClinicalTrials.gov NCT05902962 · fetched Nov 12, 2026
- Natural History of PRPF31 Mutation-Associated Retinal DystrophyACTIVE_NOT_RECRUITING · started Jul 7, 2022ClinicalTrials.gov NCT05573984 · fetched Nov 12, 2026